REG - Biofrontera AG - Ameluz® first stage approval process Israel <Origin Href="QuoteRef">B8FGn.DE</Origin>

Biofrontera AGAnnouncement

29/10/2014 11:40

RNS Number : 7184O
Biofrontera AG
11 August 2014
Ameluz has passed first stage in approval process in Israel
Leverkusen, 11 August 2014 - Biofrontera (AIM/FSE:B8F), the European biopharmaceutical company,announces that its licensee Perrigo Company plc has filed the marketing approval dossier with the Ministry of Health in Israel (IMOH). After a preliminary review, IMOH has accepted Ameluz for registration and issued a preliminary registration number, in order for the full review process to now start. The underlying exclusive license with Perrigo Israel Agencies Ltd., a subsidiary of Perrigo Company plc, to market Ameluz and BF-RhodoLED in Israel was signed earlier this year (see press release of 6 January 2014). 
The Perrigo dermatology team is the leading dermatology sales team in Israel. In a very short time, through a close collaboration between Biofrontera and Perrigo, the European approval dossier was adapted to the rules in Israel and all relevant documentation for the filing in Israel was collected. With the acceptance of the dossier by IMOH, we expect to obtain approval in Israel next year. Biofrontera's prescription drug Ameluz, for the treatment of actinic keratosis with photodynamic therapy, will be marketed in Israel under the same name.
Prof. Hermann Lbbert, Chief Executive Officer of Biofrontera commented: "Perrigo has enabled Biofrontera to accelerate its international development. The Board is delighted that we will have the opportunity to start marketing Ameluz in this new territory next year. Perrigo has the leading dermatology sales team in Israel and we are confident of a strong start to the launch of Ameluz in this new market."
In addition to the marketing approval application, the elaborate process for pricing and reimbursement required in Israel was recently initiated with the National Health Basket Committee, which is responsible for ensuring that with completion of the approval process the price and the eligibility for reimbursement are determined. 

Enquiries
Biofrontera AG 
Prof. Hermann Lbbert, Chief Executive Officer
Thomas Schaffer , Chief Financial Officer
Anke zur Mhlen, Corporate Communications
+49 (0) 214 87 63 2 0
press@biofrontera.com
www.biofrontera.com
Brainwell Asset Solutions
Jrgen Benker
+49 (0) 152 08931514
finnCap (Nomad and Broker)
Geoff Nash / Christopher Raggett (Corporate Finance)
Steven Norcross(Corporate Broking)
+44(0) 20 7220 0500
Seton Services Limited (IR)
Toni Vallen
+44 (0) 20 7603 6797
Gable Communications 
Justine James / John Bick
+44 (0) 20 7193 7463
+44 (0) 7872 061007
Notes to Editors:
Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.
In addition, the Company markets the Belixos cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lbbert, the CEO, and is headquartered in Leverkusen, Germany.
www.biofrontera.com
This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCZMGMRLGDGDZM